VX19-147-101
71 evidence topics · 9 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Primary, secondary, and exploratory objectives in the protocol
Aim of part A and part B in the published report
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2020-06-08” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2021-11-11” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2021-12-09” (opens the source at this quote in a new tab)
“Results First Posted 2023-07-10” (opens the source at this quote in a new tab)
Registered locations
Sites, countries, and enrollment period in the published report
Study design
Single-group, open-label, two-part design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment | “16” |
Cohorts defined by proteinuria at screening in the protocol
Part B off-treatment follow-up
Rationale for omitting a placebo group and for the 13-week duration
Study design and oversight
Eligibility criteria
Key eligibility criteria in the published report
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
“APOL1 genotype of G1/G1, G2/G2, or G1/G2” (opens the source at this quote in a new tab)
“FSGS diagnosed by kidney biopsy” (opens the source at this quote in a new tab)
“Evidence of non-APOL1-mediated FSGS” (opens the source at this quote in a new tab)
“Participants with known sickle cell disease” (opens the source at this quote in a new tab)
“Solid organ or Bone marrow transplant” (opens the source at this quote in a new tab)
“18 Years to 65 Years (Adult, Older Adult )” (opens the source at this quote in a new tab)
Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR
Exclusion criteria in the protocol: non-APOL1 causes of FSGS and other conditions
Treatment
Intervention in the ClinicalTrials.gov record
Rationale for the 15 mg and 45 mg doses
Restricted medications and foods in the protocol
Study outcomes
Rationale for using percent change in UPCR as the primary endpoint
Registered primary and secondary outcome measures
“Percent Change From Baseline in UPCR” (opens the source at this quote in a new tab)
“From Baseline up to Week 13” (opens the source at this quote in a new tab)
“Maximum Observed Concentration (Cmax) of VX-147” (opens the source at this quote in a new tab)
“Observed Pre-dose Concentration (Ctrough) of VX-147” (opens the source at this quote in a new tab)
Exploratory endpoints in the protocol
Sponsor rationale for UPCR as the primary endpoint and its measurement
Proteinuria and progression to end-stage kidney disease
Threshold for a clinically meaningful reduction in proteinuria
Placebo response in proteinuric CKD trials
Commentary on proteinuria reduction as an endpoint
“The degree of proteinuria reduction achieved in the phase 2A clinical trial has been shown to be associated with slowing the progression of proteinuric kidney disease and it is unlikely to be an artefact of being enrolled in a clinical trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the protocol
Sample size based on precision of the estimate
Participants enrolled and analyzed
Description of analysis sets
Primary efficacy analysis restricted to participants with at least 80% adherence
Analysis sets defined in the statistical analysis plan
Analysis populations in the posted results
Statistical methods for the primary endpoint: log-transformed geometric mean percent change
Statistical methods: confidence intervals, multiplicity, and sensitivity analyses in the statistical analysis plan
Statistical methods: descriptive safety and pharmacokinetic analyses in the protocol
Results
Participant disposition
Study parts covered by the posted results
Exclusion of participants below the adherence threshold and part B participation
Company statement on noncompliant participants
Baseline characteristics
Demographic and clinical characteristics at baseline (Table 1)
| Characteristic | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
|---|---|---|---|
| Age, years, mean ±SD | “38.8±14.5” | “45.0±10.5” | “37.3±15.2” |
| Male, no. (%) | “7 (44)” | “1 (33)” | “6 (46)” |
| Female, no. (%) | “9 (56)” | “2 (67)” | “7 (54)” |
| APOL1 genotype G1/G1, no. (%) | “9 (56)” | “3 (100)” | “6 (46)” |
| APOL1 genotype G2/G2, no. (%) | “1 (6)” | “0” | “1 (8)” |
| APOL1 genotype G1/G2, no. (%) | “6 (38)” | “0” | “6 (46)” |
| Body-mass index, mean ±SD | “29.6±6.4” | “32.7±6.4” | “28.9±6.4” |
| Urinary protein-to-creatinine ratio, mean ±SD | “2.08±0.90” | “3.47±1.07” | “1.77±0.49” |
| Estimated GFR, ml/min/1.73 m2, mean ±SD | “51.2±14.0” | “51.4±22.2” | “51.2±12.8” |
| ACE inhibitor ≥28 days before day 1, no. (%) | “8 (50)” | “1 (33)” | “7 (54)” |
| Angiotensin-receptor blocker ≥28 days before day 1, no. (%) | “7 (44)” | “3 (100)” | “4 (31)” |
| Immunosuppressants ≥28 days before day 1, no. (%) | “4 (25)” | “1 (33)” | “3 (23)” |
Baseline UPCR in the efficacy population and similarity across subgroups
Efficacy results
Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)
| Measure | Total (N=13) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=10) |
|---|---|---|---|
| Mean UPCR at baseline, ±SD | “2.21±0.95” | “3.47±1.07” | “1.84±0.52” |
| Mean UPCR at week 13, ±SD | “1.27±0.73” | “1.83±0.58” | “1.10±0.71” |
| Geometric percent change from baseline at week 13 (95% CI) | “−47.6 (−60.0 to −31.3)” | “−47.7 (−70.1 to −8.5)” | “−47.5(−63.4 to −24.6)” |
Primary endpoint in the published abstract
Time course of proteinuria reduction
Analysis of all 16 participants regardless of adherence
Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)
| Measure | Quoted record |
|---|---|
| Outcome measure | “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147” |
| Time frame | “Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5” |
| Overall number of participants analyzed | “13” |
| Mean (standard deviation), h*mcg/mL | “15.3(6.37)” |
Company statement of the primary endpoint result
Health-related quality of life and patient-reported outcomes
SF-36 planned as an exploratory endpoint
SF-36 results
No evidence found.
Safety results
Overview of adverse events
Adverse events (Table 3)
| Event, no. (%) | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
|---|---|---|---|
| Any adverse event | “15 (94)” | “3 (100)” | “12 (92)” |
| Mild | “7 (44)” | “1 (33)” | “6 (46)” |
| Moderate | “8 (50)” | “2 (67)” | “6 (46)” |
| Serious adverse event | “1 (6)” | “0” | “1 (8)” |
| Headache | “4 (25)” | “1 (33)” | “3 (23)” |
| Back pain | “3 (19)” | “0” | “3 (23)” |
| Nausea | “3 (19)” | “1 (33)” | “2 (15)” |
| Decrease in blood bicarbonate level | “2 (12)” | “0” | “2 (15)” |
| Diarrhea | “2 (12)” | “1 (33)” | “1 (8)” |
| Dizziness | “2 (12)” | “0” | “2 (15)” |
| Dyspepsia | “2 (12)” | “0” | “2 (15)” |
| Fatigue | “2 (12)” | “0” | “2 (15)” |
Laboratory values, electrocardiograms, vital signs, and eGFR
Deaths, serious adverse events, and other adverse events in the posted results
| Measure, affected / at risk (%) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| All-cause mortality | “0/3 (0.00%)” | “0/13 (0.00%)” | “0/16 (0.00%)” |
| Serious adverse events, total | “0/3 (0.00%)” | “1/13 (7.69%)” | “1/16 (6.25%)” |
| Other (not including serious) adverse events, total | “3/3 (100.00%)” | “12/13 (92.31%)” | “15/16 (93.75%)” |
Adverse events in investigations and cardiac disorders in the posted results
| Event | Total, affected / at risk (%) |
|---|---|
| Blood bicarbonate decreased | “2/16 (12.50%)” |
| Blood creatine phosphokinase increased | “1/16 (6.25%)” |
| Electrocardiogram ST segment depression | “1/16 (6.25%)” |
| Gamma-glutamyltransferase increased | “1/16 (6.25%)” |
| Transaminases increased | “1/16 (6.25%)” |
| Palpitations | “1/16 (6.25%)” |
Study limitations
Summary: study limitations
VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.
Limitations stated by the investigators
Other APOL1-mediated kidney disease phenotypes not studied
Commentary: lack of randomization, population, and endpoint
“First, this is not a randomized control trial, there is therefore a need for a phase 3 clinical trial of inaxaplin + standard of care versus placebo + standard of care before clinical use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, the study was carried out in a small population of participants from Europe and North America.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This point is especially important since Africans living in Africa were not part of this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, reduction in proteinuria was used as the primary end point for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote